OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
00214156

Infund Holding Co Ltd

PharmaceuticalsVerified

Infund Holding Co Ltd maintains a relatively strong liquidity position, with a current ratio of 2.67, indicating that it has more than twice as many current assets as current liabilities. However, the company's liquidity is assessed as medium risk, and its net cash position is negative after subtracting total debt, suggesting potential short-term financial strain. The company's debt-to-equity ratio of 0.28 indicates a conservative capital structure, with equity significantly outweighing debt. In terms of profitability, Infund Holding Co Ltd reported a net income of 15,697,170 CNY in the latest period, but its operating income was negative at -647,630 CNY, signaling operational inefficiencies or cost overruns. The return on equity (ROE) of 1.96% and return on assets (ROA) of 1.3% are below the typical thresholds for strong performance in the pharmaceutical industry, suggesting that the company is not generating robust returns relative to its equity and asset base. The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic diversification provided in the available data. This lack of segment and geographic diversification could expose the company to higher concentration risk, particularly if demand for its products or services declines in its primary market. Looking ahead, the company's growth trajectory appears uncertain. The latest financial data does not provide forward-looking revenue guidance, and the absence of a clear growth strategy or significant capital expenditure plans suggests limited near-term expansion. The company's free cash flow of 36,249,320 CNY and operating cash flow of 55,384,780 CNY indicate some capacity to fund operations and potentially invest in growth, but the negative operating income raises concerns about long-term sustainability. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's shares outstanding are the same for both basic and diluted shares, indicating no imminent threat of equity dilution. However, the negative net cash position after subtracting total debt is a red flag, as it may limit the company's ability to meet short-term obligations without external financing. No recent events, such as filings or transcripts, are available in the provided data to inform the company's strategic direction or operational changes. This lack of recent disclosures may limit the ability to assess the company's response to market conditions or regulatory developments.

30-day price · 002141(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyInfund Holding Co Ltd
Ticker002141.SZ
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Infund Holding Co Ltd is a pharmaceutical company that generates revenue primarily through the development and sale of medical products and services.

Classification. Infund Holding Co Ltd is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, with a classification confidence of 0.92.

Infund Holding Co Ltd maintains a relatively strong liquidity position, with a current ratio of 2.67, indicating that it has more than twice as many current assets as current liabilities. However, the company's liquidity is assessed as medium risk, and its net cash position is negative after subtracting total debt, suggesting potential short-term financial strain. The company's debt-to-equity ratio of 0.28 indicates a conservative capital structure, with equity significantly outweighing debt. In terms of profitability, Infund Holding Co Ltd reported a net income of 15,697,170 CNY in the latest period, but its operating income was negative at -647,630 CNY, signaling operational inefficiencies or cost overruns. The return on equity (ROE) of 1.96% and return on assets (ROA) of 1.3% are below the typical thresholds for strong performance in the pharmaceutical industry, suggesting that the company is not generating robust returns relative to its equity and asset base. The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic diversification provided in the available data. This lack of segment and geographic diversification could expose the company to higher concentration risk, particularly if demand for its products or services declines in its primary market. Looking ahead, the company's growth trajectory appears uncertain. The latest financial data does not provide forward-looking revenue guidance, and the absence of a clear growth strategy or significant capital expenditure plans suggests limited near-term expansion. The company's free cash flow of 36,249,320 CNY and operating cash flow of 55,384,780 CNY indicate some capacity to fund operations and potentially invest in growth, but the negative operating income raises concerns about long-term sustainability. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's shares outstanding are the same for both basic and diluted shares, indicating no imminent threat of equity dilution. However, the negative net cash position after subtracting total debt is a red flag, as it may limit the company's ability to meet short-term obligations without external financing. No recent events, such as filings or transcripts, are available in the provided data to inform the company's strategic direction or operational changes. This lack of recent disclosures may limit the ability to assess the company's response to market conditions or regulatory developments.
Key takeaways
  • Infund Holding Co Ltd has a conservative capital structure with a debt-to-equity ratio of 0.28, but its liquidity is assessed as medium risk due to a negative net cash position after subtracting total debt.
  • The company's profitability is weak, with a negative operating income and low ROE and ROA, indicating poor returns on equity and assets.
  • Revenue is concentrated in a single business segment, and no geographic diversification is disclosed, increasing concentration risk.
  • Free cash flow and operating cash flow are positive, but the lack of forward-looking guidance and limited capital expenditure suggest limited growth potential.
  • The company's shares are not currently at risk of dilution, but its liquidity position requires close monitoring.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$1.16B
Gross profit$73.4M
Operating income-$647.6k
Net income$15.7M
R&D
SG&A
D&A
SBC
Operating cash flow$55.4M
CapEx-$4.9M
Free cash flow$36.2M
Total assets$1.20B
Total liabilities$402.1M
Total equity$801.3M
Cash & equivalents
Long-term debt$225.4M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$801.3M
Net cash-$225.4M
Current ratio2.7
Debt/Equity0.3
ROA1.3%
ROE2.0%
Cash conversion3.5%
CapEx/Revenue-0.4%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 1 companies
Metric002141Activity
Op margin-0.1%-2.9% medp25 -218.9% · p75 9.6%above median
Net margin1.4%28.2% medp25 28.2% · p75 28.2%bottom quartile
Gross margin6.3%47.8% medp25 27.6% · p75 68.9%bottom quartile
CapEx / revenue-0.4%6.6% medp25 6.6% · p75 6.6%bottom quartile
Debt / equity28.0%271.5% medp25 271.5% · p75 271.5%bottom quartile
Source: analysis-pipeline (hybrid)Generated: 2026-05-19 23:53 UTCJob: 1d1ebb14